BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Their core programs focus on the treatment of disc/spine disease and metabolic disorders.

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs.

• Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

NSF Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

📣 BioRestorative Therapies announced that it has entered into a strategic supply agreement with Evolutionary Biologics, a supplier of biologic-based cosmetics into the $70BN cosmetic and aesthetics industry.

Pursuant to the supply agreement, BioRestorative, using its cGMP ISO-7 certified clean room, will manufacture tissue-based biologics for Evolutionary Biologics for cosmetic and aesthetic applications. 

The first-generation product, that has been formulated and manufactured, is an umbilical cord tissue extract that is highly enriched with factors that address the signs of aging. These factors include cytokines, chemokines, growth factors and exosomes, which are known to play important roles as communication mediators between cells and have been found to have certain anti-aging effects on skin.”

Stay up to date on all of our latest press releases here: https://lnkd.in/epTs4uYt

Happy Thanksgiving from all of us at Biorestorative Therapies. We hope that your day is filled with gratitude and appreciation! 🦃🍁

https://lnkd.in/eKgzhkfY
Company      BioRestorative Therapies, Inc.
Presenter      Lance Alstodt, Chief Executive Officer
Date & Time    Thursday October 12th, 9:00am est
Location       Yale Club, 50 Vanderbilt Avenue, NYC


✨ Check out our new press release announcing BioRestorative’s supply agreement with Evolutionary Biologics:

“This is a very exciting time for BioRestorative Therapies as we seek to develop our recent strategic partnerships. Leveraging our ISO-7 certified clean room to formulate and manufacture a commercial product in the $62.8 billion global aesthetics market is not only a thrilling opportunity but it allows us to scale and drive efficiencies going forward as we seek to expand our commercial business model.”

👉 Read the latest press releases here: https://lnkd.in/epTs4uYt

📣 We are thrilled to announce the Activation of Northwell Health in BioRestorative’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease.

“I’m pleased to report that, after several months of a deliberate and thoughtful collaboration with Northwell Health, the largest healthcare provider and employer in New York State, we have reached the point of initiating the patient enrollment process. 

Given the size of Northwell Health and its relative proximity to our facilities in Melville, New York, we look forward to significant benefits from working with Northwell Health in connection with our Phase 2 clinical trial. We hope that our partnership will result in a highly efficient recruitment / enrollment process among other significant benefits,” stated Lance Alstodt, Chief Executive Officer of BioRestorative.”

👉 Read the latest press releases here: https://lnkd.in/epTs4uYt

Meet the team at BioRestorative✅

Dr. Jason Lipetz is the chairman of the Disc Advisory board. He is the founder of Long Island Spine Rehabilitation Medicine, a prominent spine and musculoskeletal care center specializing in the non-surgical treatment of the spine and orthopedic rehabilitation.

We are lucky to have him on our team as we further the research and development of BRTX-100 our stem cell product candidate for degenerative disc disease.

💻 https://lnkd.in/eiGkkBzw 
📱 631-760-8100

COM:BIORESTORATIVE

BioRestorative Therapies, Inc.

Last Close

1.63

30/08 20:00

Market Cap

12.12M

Beta: -

Volume Today

13.63K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

Metrics